Veracyte

Veracyte Net Debt / EBITDA

The Net Debt to EBITDA of Veracyte (VCYT) as of Oct 25, 2026 is -5.03. In the previous year, Net Debt to EBITDA was -11.67 — a change of -56.88% (higher).

Net Debt / EBITDA

-5.03

YoY

-56.88%

Last updated:

Net Debt to EBITDA of Veracyte is 2025 -5.03 . Net Debt to EBITDA of Veracyte was 2024 -11.67 . It decreases by -56.88% higher compared to the previous year.

The Veracyte Net Debt / EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt / EBITDA
Date
Net Debt / EBITDA
Jan 1, 2018
2.94 USD
Jan 1, 2019
13.19 USD
Jan 1, 2020
12.24 USD
Jan 1, 2021
2.75 USD
Jan 1, 2022
10.51 USD
Jan 1, 2023
3.56 USD
Jan 1, 2024
-11.67 USD
Jan 1, 2025
-5.03 USD
The Veracyte Net Debt / EBITDA history
YEARNet Debt / EBITDAYoY
-5.03-56.88%
-11.67-427.88%
3.56-66.14%
10.51+282.14%
2.75-77.52%
12.24-7.23%
13.19+348.90%
2.94+795.99%
0.33-73.26%
1.23+17.51%
1.04-1.23%
1.06-82.20%
5.93+301.16%
1.48+48.91%
0.99—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Veracyte Stock analysis

What does Veracyte do? Veracyte Inc is a company that specializes in the development and marketing of diagnostic tests for a wide range of diseases and disorders. The company was founded in 2008 and is headquartered in South San Francisco, California. The history of Veracyte Inc begins with the vision to help patients with better diagnostic options. The company has used its expertise in gene expression technology to develop tests that facilitate the diagnosis of diseases and disorders in various areas, such as cancer, thyroid diseases, and lung diseases. Veracyte Inc's business model is based on selling diagnostic tests to healthcare facilities, hospitals, doctors, and other medical institutions. The tests are performed by specially trained professionals and can provide a precise diagnosis that helps doctors plan individualized treatment. Veracyte Inc is divided into different divisions to offer the best and most precise test for each area. The divisions include cancer diagnosis, thyroid diagnostics, lung diagnostics, and other areas of gene expression technology. In cancer diagnosis, Veracyte Inc offers tests for various types of cancer, such as breast cancer, thyroid cancer, and lung cancer. The tests use RNA sequencing to analyze the patient's genetic information and provide a more precise diagnosis. In thyroid diagnostics, Veracyte Inc offers tests for various thyroid diseases that are often difficult to diagnose. The tests help avoid unnecessary surgeries or medical interventions and enable patients to receive a more accurate diagnosis and treatment. In lung diagnostics, Veracyte Inc offers tests for pneumonia, lung cancer, and other lung diseases. The tests use RNA sequencing and imaging to provide accurate diagnoses that help doctors recommend tailored treatment. In addition to these divisions, Veracyte Inc also offers other products and services, such as information campaigns and training for healthcare professionals, as well as support and counseling for patients and their families. Overall, Veracyte Inc aims to revolutionize the medical field and provide patients with better diagnosis and treatment options. The company's tests offer doctors and patients a more precise and personalized diagnosis, allowing for individualized treatment and achieving the best results. Veracyte is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Veracyte stock

Net Debt to EBITDA of Veracyte is -5.03 in 2025.

Net Debt to EBITDA of Veracyte changed from -11.67 to -5.03, representing a -56.88% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to EBITDA Veracyte since 2006 – with annual values, charts, and detailed analysis.

Net Debt/EBITDA measures how many years it would take to repay all debt using EBITDA. Lower ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to EBITDA's Veracyte with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Veracyte

All Key Metrics — Veracyte